Evidence map›Paper›PMID 17068080›Full record

ArticleNucleic acids research2006

Functional interactions between Dlx2 and lymphoid enhancer factor regulate Msx2.

Evan Diamond, Melanie Amen, Qiaoyan Hu, Herbert M Espinoza, Brad A Amendt

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 28 citations in OpenAlex.

  1. AnFrontiers in physiology · 2020
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Regulation of calbindin-D(28k) expression by Msx2 in the dental epithelium.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2012
    Article
  11. Article
  12. Article
  13. Article
  14. Chromatin protein HMGB2 regulates articular cartilage surface maintenance via beta-catenin pathway.Proceedings of the National Academy of Sciences of the United States of America · 2009
    Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Evan DiamondCenter for Environmental and Genetic Medicine, Institute of Biosciences and Genetic Medicine Texas A&M Health Science Center, 2121 W. Holcombe Boulevard, Houston, TX 77030, USA.
Melanie Amen
Qiaoyan Hu
Herbert M Espinoza
Brad A Amendt
Texas A&M Health Science Center · USTexas A&M Health Science Center · US

Funding

Pilot--Health Science ResearchP30ES009106 · NIEHS · TEXAS A&M UNIVERSITY SYSTEM · PI SAFE, STEPHEN H. · 1998 to 2006
$9.2M
Molecular Mechanisms of PITX2 During Craniofacial DevelopmentR01DE013941 · NIDCR · UNIVERSITY OF TULSA · PI AMENDT, BRAD A · 2000 to 2013
$4.2M
NIDCR NIH HHS DE13941NIDCR NIH HHS R01 DE013941NIEHS NIH HHS ES09106NIEHS NIH HHS P30 ES009106
6 · The paper itself

Abstract

Dlx2, Lymphoid Enhancer Factor (Lef-1) and Msx2 transcription factors are required for several developmental processes. To understand the control of gene expression by these factors, chromatin immunoprecipitation (ChIP) assays identified Msx2 as a downstream target of Dlx2 and Lef-1. Dlx2 activates the Msx2 promoter in several cell lines and binds DNA as a monomer and dimer. A Lef-1 beta-catenin-dependent isoform minimally activates the Msx2 promoter and a Lef-1 beta-catenin-independent isoform is inactive, however co-expression of Dlx2 and both Lef-1 isoforms synergistically activate the Msx2 promoter. Co-immunoprecipitation and protein pull-down experiments demonstrate Lef-1 physically interacts with Dlx2. Deletion analyses of the Lef-1 protein reveal specific regions required for synergism with Dlx2. The Lef-1 beta-catenin binding domain (betaDB) is not required for its interaction with Dlx2. Msx2 can auto-regulate its promoter and repress Dlx2 activation. Msx2 repression of Dlx2 activation is dose-specific and both bind a common DNA-binding element. These transcriptional mechanisms correlate with the temporal and spatial expression of these factors and may provide a mechanism for the control of several developmental processes. We demonstrate new transcriptional activities for Dlx2, Msx2 and Lef-1 through protein interactions and identification of downstream targets.

Indexed as

Transcriptional ActivationAnimalsBinding SitesCell LineChromatin ImmunoprecipitationDNA-Binding ProteinsHomeodomain ProteinsLymphoid Enhancer-Binding Factor 1Promoter Regions, GeneticProtein Structure, TertiaryTranscription FactorsDistal-less homeobox proteinsDNA-Binding ProteinsHomeodomain ProteinsLymphoid Enhancer-Binding Factor 1MSX2 proteinTranscription Factors

Identifiers

PMID17068080
PMCPMC1635299
OpenAlexW1978727508

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.